Regado Biosciences Inc (RGDO) 0.89 $RGDO
Venous Thromboembolism - Pipeline Review, H2 2014
M2 - Fri Dec 12, 4:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/h48x9c/venous) has announced the addition of the "Venous Thromboembolism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Venous Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Thromboembolism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Venous Thromboembolism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Venous Thromboembolism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Sanofi - Isis Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Bayer AG - Portola Pharmaceuticals, Inc. - Green Cross Corporation - Regado Biosciences, Inc. - GlycoMimetics, Inc. - Gamma Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/h48x9c/venous
PTLA: 28.27 (-0.27), ISIS: 62.32 (+0.45), GLYC: 9.00 (+0.49), RGDO: 0.89 (+0.02)
Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2014
M2 - Mon Dec 08, 3:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/l6bhq9/deep_vein) has announced the addition of the "Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Deep Vein Thrombosis (DVT), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Deep Vein Thrombosis (DVT) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Deep Vein Thrombosis (DVT) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Deep Vein Thrombosis (DVT) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Generex Biotechnology Corporation - Bayer AG - Merrion Pharmaceuticals Plc - Regado Biosciences, Inc. - Thrombotargets Corporation - Diakron Pharmaceuticals, Inc. - Armetheon, Inc. For more information visit http://www.researchandmarkets.com/research/l6bhq9/deep_vein
BMY: 58.75 (-0.93), RGDO: 0.89 (+0.02)
Biotech Weekly: Here Come The Institutional Holdings Updates
Daniel Ward - at Seeking Alpha - Mon Nov 17, 7:31AM CST
LOXO: 11.13 (-0.92), TRGT: 2.46 (-0.01), BOTA: 2.32 (+0.05), XBI: 183.73 (-0.31), IBB: 306.10 (-3.95), BIOS: 5.91 (-0.12), RGDO: 0.89 (+0.02), EXEL: 1.40 (unch), AMPH: 11.73 (+0.02)
Regado Biosciences' (RGDO) CEO Michael Metzger on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 9:17AM CST
RGDO: 0.89 (+0.02)
Regado Biosciences beats by $1.04
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 5:14PM CST
RGDO: 0.89 (+0.02)
Regado Biosciences Announces Third Quarter 2014 Financial Results and Provides Corporate Update
PR Newswire - Wed Nov 05, 3:30PM CST
Regado Biosciences, Inc. (Nasdaq: RGDO), today announced its third quarter 2014 financial results. A conference call and webcast to discuss the results will be held tomorrow, November 6, 2014, at 8:30 a.m. EST.
RGDO: 0.89 (+0.02)
Regado Biosciences to Provide Third Quarter 2014 Financial Results
PR Newswire - Thu Oct 30, 6:30AM CDT
Regado Biosciences, Inc. (Nasdaq: RGDO), today announced that it will hold a conference call and live audio webcast on Thursday, November 6, 2014, at 8:30 a.m. EST to discuss its third quarter 2014 financial results.
RGDO: 0.89 (+0.02)
Regado Biosciences: Significant Value Remains After Lead Drug Failure
Daniel Ward - at Seeking Alpha - Tue Oct 28, 6:50AM CDT
RGDO: 0.89 (+0.02)
5 Stocks Ready to Break Out and Soar Higher
at The Street - Mon Oct 20, 9:24AM CDT
These stocks look ready to break out and trade higher from current levels.
VJET: 8.27 (+0.35), RWLK: 21.22 (-0.28), PLX: 2.10 (+0.07), NDLS: 25.82 (+0.24), RGDO: 0.89 (+0.02)
Regado Biosciences' president gets additional title
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 4:39PM CDT
RGDO: 0.89 (+0.02)
3 Biotech Stocks Under $10 in Breakout Territory
at The Street - Wed Oct 15, 6:00AM CDT
Keep these under-$10 biotech stocks on your breakout trading radar.
ATNM: 5.95 (-0.10), RCPI: 0.14 (-0.01), RGDO: 0.89 (+0.02)
Regado Biosciences names Michael A. Metzger as CEO
M2 - Mon Oct 13, 3:05AM CDT
Biopharmaceutical company Regado Biosciences (NasdaqCM:RGDO) disclosed on Friday the addition of Michael A. Metzger to the additional post of chief executive officer plus as a member of its board of directors.
RGDO: 0.89 (+0.02)
Regado Biosciences Appoints Michael A. Metzger CEO
PR Newswire - Fri Oct 10, 6:30AM CDT
Regado Biosciences, Inc. (NASDAQ: RGDO), today announced the appointment of Michael A. Metzger, president of Regado, to the additional post of chief executive officer and as a member of the Board of Directors effective immediately. Mr. Metzger previously served as president and chief operating officer of Regado. He replaces David J. Mazzo, Ph.D., who has resigned from the company.
RGDO: 0.89 (+0.02)
CorMedix Files IND Application for Neutrolin in the US - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 4:10PM CDT
CorMedix Inc. (CRMD) announced that it has filed an Investigational New Drug (IND) application to the FDA for Neutrolin.
CRMD: 1.39 (-0.04), CBM: 23.66 (+0.24), GILD: 104.13 (-0.18), RGDO: 0.89 (+0.02)
Regado Trims Workforce, Revamps Strategy on Trial Halt - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 3:30PM CDT
Regado (RGDO) has reduced its work force by almost 60%.
MNK: 94.72 (-0.36), MDVN: 106.86 (-1.16), GILD: 104.13 (-0.18), RGDO: 0.89 (+0.02)
3 Biotech Stocks Under $10 to Trade for Breakouts
at The Street - Fri Sep 26, 8:12AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
MACK: 10.64 (+0.42), BOTA: 2.32 (+0.05), RGDO: 0.89 (+0.02)
Biotech Stocks Technical Insight - Incyte, Regado Biosciences, ACADIA Pharma, Pharmacyclics, and Raptor Pharma
PR Newswire - Fri Sep 26, 7:45AM CDT
The US markets on Thursday, September 25, 2014, declined with the Dow Jones Industrial Average finishing at 16,945.80, down 1.54% and the NASDAQ Composite closing at 4,466.75, down 1.94%. The S&P 500 ended the session 1.62% lower at 1,965.99. During the trading session, all the ten sectors finished on a negative note. The S&P 500 Health Care Sector Index closed the day at 743.47, down 1.58%, whereas the index has advanced 4.99% in the previous three months. Investor-Edge has initiated coverage on the following equities: Incyte Corporation (NASDAQ: INCY), Regado Biosciences Inc. (NASDAQ: RGDO), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Pharmacyclics Inc. (NASDAQ: PCYC), and Raptor Pharmaceutical Corporation (NASDAQ: RPTP). Free research on these five companies can be accessed at:
ACAD: 32.53 (-0.10), PCYC: 132.65 (-2.34), RPTP: 8.44 (+0.22), INCY: 74.65 (-1.27), RGDO: 0.89 (+0.02)
Market Maker Surveillance Report. IG, CNET, STV, AIXG, MDBX, RGDO, Winning Stocks With Lowest Price Friction For Thursday, September 25th 2014
M2 - Fri Sep 26, 3:29AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4456 companies with "abnormal" market making, 1102 companies with positive Friction Factors and 4256 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Thursday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. IGI Laboratories Inc (NYSE:IG), Chinanet Online Holdings Inc (NASDAQ:CNET), China Digital Tv Holding Co Ltd (NYSE:STV), Aixtron SE (NASDAQ:AIXG), (OTC:MDBX), (NASDAQ:RGDO). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
AIXG: 11.10 (-0.14), STV: 3.43 (+0.02), CNET: 1.12 (-0.16), IG: 8.78 (+0.12), RGDO: 0.89 (+0.02)
Seattle Genetics' Adcetris Positive in Durability Analysis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 5:27PM CDT
Seattle Genetics, Inc. (SGEN) announced data from a two-year durability analysis of a phase I study on Adcetris for newly diagnosed mature T-cell lymphoma (MTCL).
GILD: 104.13 (-0.18), SGEN: 32.25 (-1.49), AMGN: 164.53 (-1.55), RGDO: 0.89 (+0.02)
Novavax's Influenza Vaccine Study Shows Adjuvant Efficiency - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 5:10PM CDT
Novavax, Inc. (NVAX) announced positive top-line data from a phase I/II study on influenza vaccine candidate, H7N9 VLP.
MDVN: 106.86 (-1.16), GILD: 104.13 (-0.18), NVAX: 5.76 (-0.17), RGDO: 0.89 (+0.02)
Venous Thromboembolism - Pipeline Review, H2 2014
M2 - Fri Dec 12, 4:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/h48x9c/venous) has announced the addition of the "Venous Thromboembolism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Venous Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Thromboembolism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Venous Thromboembolism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Venous Thromboembolism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Sanofi - Isis Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Bayer AG - Portola Pharmaceuticals, Inc. - Green Cross Corporation - Regado Biosciences, Inc. - GlycoMimetics, Inc. - Gamma Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/h48x9c/venous
PTLA: 28.27 (-0.27), ISIS: 62.32 (+0.45), GLYC: 9.00 (+0.49), RGDO: 0.89 (+0.02)
Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2014
M2 - Mon Dec 08, 3:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/l6bhq9/deep_vein) has announced the addition of the "Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Deep Vein Thrombosis (DVT), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Deep Vein Thrombosis (DVT) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Deep Vein Thrombosis (DVT) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Deep Vein Thrombosis (DVT) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Generex Biotechnology Corporation - Bayer AG - Merrion Pharmaceuticals Plc - Regado Biosciences, Inc. - Thrombotargets Corporation - Diakron Pharmaceuticals, Inc. - Armetheon, Inc. For more information visit http://www.researchandmarkets.com/research/l6bhq9/deep_vein
BMY: 58.75 (-0.93), RGDO: 0.89 (+0.02)
Biotech Weekly: Here Come The Institutional Holdings Updates
Daniel Ward - at Seeking Alpha - Mon Nov 17, 7:31AM CST
LOXO: 11.13 (-0.92), TRGT: 2.46 (-0.01), BOTA: 2.32 (+0.05), XBI: 183.73 (-0.31), IBB: 306.10 (-3.95), BIOS: 5.91 (-0.12), RGDO: 0.89 (+0.02), EXEL: 1.40 (unch), AMPH: 11.73 (+0.02)
Regado Biosciences' (RGDO) CEO Michael Metzger on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 9:17AM CST
RGDO: 0.89 (+0.02)
Regado Biosciences beats by $1.04
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 5:14PM CST
RGDO: 0.89 (+0.02)
Regado Biosciences Announces Third Quarter 2014 Financial Results and Provides Corporate Update
PR Newswire - Wed Nov 05, 3:30PM CST
Regado Biosciences, Inc. (Nasdaq: RGDO), today announced its third quarter 2014 financial results. A conference call and webcast to discuss the results will be held tomorrow, November 6, 2014, at 8:30 a.m. EST.
RGDO: 0.89 (+0.02)
Regado Biosciences to Provide Third Quarter 2014 Financial Results
PR Newswire - Thu Oct 30, 6:30AM CDT
Regado Biosciences, Inc. (Nasdaq: RGDO), today announced that it will hold a conference call and live audio webcast on Thursday, November 6, 2014, at 8:30 a.m. EST to discuss its third quarter 2014 financial results.
RGDO: 0.89 (+0.02)
Regado Biosciences: Significant Value Remains After Lead Drug Failure
Daniel Ward - at Seeking Alpha - Tue Oct 28, 6:50AM CDT
RGDO: 0.89 (+0.02)
5 Stocks Ready to Break Out and Soar Higher
at The Street - Mon Oct 20, 9:24AM CDT
These stocks look ready to break out and trade higher from current levels.
VJET: 8.27 (+0.35), RWLK: 21.22 (-0.28), PLX: 2.10 (+0.07), NDLS: 25.82 (+0.24), RGDO: 0.89 (+0.02)
Regado Biosciences' president gets additional title
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 4:39PM CDT
RGDO: 0.89 (+0.02)
3 Biotech Stocks Under $10 in Breakout Territory
at The Street - Wed Oct 15, 6:00AM CDT
Keep these under-$10 biotech stocks on your breakout trading radar.
ATNM: 5.95 (-0.10), RCPI: 0.14 (-0.01), RGDO: 0.89 (+0.02)
Regado Biosciences names Michael A. Metzger as CEO
M2 - Mon Oct 13, 3:05AM CDT
Biopharmaceutical company Regado Biosciences (NasdaqCM:RGDO) disclosed on Friday the addition of Michael A. Metzger to the additional post of chief executive officer plus as a member of its board of directors.
RGDO: 0.89 (+0.02)
Regado Biosciences Appoints Michael A. Metzger CEO
PR Newswire - Fri Oct 10, 6:30AM CDT
Regado Biosciences, Inc. (NASDAQ: RGDO), today announced the appointment of Michael A. Metzger, president of Regado, to the additional post of chief executive officer and as a member of the Board of Directors effective immediately. Mr. Metzger previously served as president and chief operating officer of Regado. He replaces David J. Mazzo, Ph.D., who has resigned from the company.
RGDO: 0.89 (+0.02)
CorMedix Files IND Application for Neutrolin in the US - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 4:10PM CDT
CorMedix Inc. (CRMD) announced that it has filed an Investigational New Drug (IND) application to the FDA for Neutrolin.
CRMD: 1.39 (-0.04), CBM: 23.66 (+0.24), GILD: 104.13 (-0.18), RGDO: 0.89 (+0.02)
Regado Trims Workforce, Revamps Strategy on Trial Halt - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 3:30PM CDT
Regado (RGDO) has reduced its work force by almost 60%.
MNK: 94.72 (-0.36), MDVN: 106.86 (-1.16), GILD: 104.13 (-0.18), RGDO: 0.89 (+0.02)
3 Biotech Stocks Under $10 to Trade for Breakouts
at The Street - Fri Sep 26, 8:12AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
MACK: 10.64 (+0.42), BOTA: 2.32 (+0.05), RGDO: 0.89 (+0.02)
Biotech Stocks Technical Insight - Incyte, Regado Biosciences, ACADIA Pharma, Pharmacyclics, and Raptor Pharma
PR Newswire - Fri Sep 26, 7:45AM CDT
The US markets on Thursday, September 25, 2014, declined with the Dow Jones Industrial Average finishing at 16,945.80, down 1.54% and the NASDAQ Composite closing at 4,466.75, down 1.94%. The S&P 500 ended the session 1.62% lower at 1,965.99. During the trading session, all the ten sectors finished on a negative note. The S&P 500 Health Care Sector Index closed the day at 743.47, down 1.58%, whereas the index has advanced 4.99% in the previous three months. Investor-Edge has initiated coverage on the following equities: Incyte Corporation (NASDAQ: INCY), Regado Biosciences Inc. (NASDAQ: RGDO), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Pharmacyclics Inc. (NASDAQ: PCYC), and Raptor Pharmaceutical Corporation (NASDAQ: RPTP). Free research on these five companies can be accessed at:
ACAD: 32.53 (-0.10), PCYC: 132.65 (-2.34), RPTP: 8.44 (+0.22), INCY: 74.65 (-1.27), RGDO: 0.89 (+0.02)
Market Maker Surveillance Report. IG, CNET, STV, AIXG, MDBX, RGDO, Winning Stocks With Lowest Price Friction For Thursday, September 25th 2014
M2 - Fri Sep 26, 3:29AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4456 companies with "abnormal" market making, 1102 companies with positive Friction Factors and 4256 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Thursday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. IGI Laboratories Inc (NYSE:IG), Chinanet Online Holdings Inc (NASDAQ:CNET), China Digital Tv Holding Co Ltd (NYSE:STV), Aixtron SE (NASDAQ:AIXG), (OTC:MDBX), (NASDAQ:RGDO). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
AIXG: 11.10 (-0.14), STV: 3.43 (+0.02), CNET: 1.12 (-0.16), IG: 8.78 (+0.12), RGDO: 0.89 (+0.02)
Seattle Genetics' Adcetris Positive in Durability Analysis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 5:27PM CDT
Seattle Genetics, Inc. (SGEN) announced data from a two-year durability analysis of a phase I study on Adcetris for newly diagnosed mature T-cell lymphoma (MTCL).
GILD: 104.13 (-0.18), SGEN: 32.25 (-1.49), AMGN: 164.53 (-1.55), RGDO: 0.89 (+0.02)
Novavax's Influenza Vaccine Study Shows Adjuvant Efficiency - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 5:10PM CDT
Novavax, Inc. (NVAX) announced positive top-line data from a phase I/II study on influenza vaccine candidate, H7N9 VLP.
MDVN: 106.86 (-1.16), GILD: 104.13 (-0.18), NVAX: 5.76 (-0.17), RGDO: 0.89 (+0.02)
